Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

T-cell Infusion Targeting BCMA and CD19 for Refractory/Relapsed Systemic Lupus Erythematosus (SLE) Patients With or Without Organs Involvement

NCT06350110 is registered in ClinicalTrials.gov with Essen Biotech as lead sponsor.

NCT NCT06350110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06350110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
T-cell Infusion Targeting BCMA and CD19 for Refractory/Relapsed Systemic Lupus Erythematosus (SLE) Patients With or Without Organs Involvement
Lead sponsor
Essen Biotech
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 10, 2024
Completion date
December 28, 2025
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune diseases, granulomatous polyangiitis, idiopathic inflammatory myopathies, lupus nephritis, microscopic polyangiitis, sjogren's syndrome, systemic lupus erythematosus, systemic sclerosis